83 FR 30756 - Request for Information on the HEALing Communities Study: Developing and Testing an Integrated Approach To Address the Opioid Crisis
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health Federal Register Volume 83, Issue 126 (June 29, 2018)
National Institutes of Health
Federal Register Volume 83, Issue 126 (June 29, 2018)
| Page Range | 30756-30757 | |
| FR Document | 2018-14031 |
[Federal Register Volume 83, Number 126 (Friday, June 29, 2018)] [Notices] [Pages 30756-30757] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2018-14031] [[Page 30756]] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Request for Information on the HEALing Communities Study: Developing and Testing an Integrated Approach To Address the Opioid Crisis AGENCY: National Institutes of Health; Substance Abuse and Mental Health Services Administration, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: This Request for Information (RFI) is intended to gather broad public input on the conduct of a multi-site national research effort to develop and test approaches for the systematic implementation and sustainability of an integrated set of evidence-based interventions across healthcare, behavioral health, justice systems, state and local governments, and community organizations to prevent and treat opioid misuse and Opioid Use Disorders (OUD). The goals are to decrease fatal and non-fatal overdoses, decrease the incidence of OUD and related infectious diseases (e.g., Hepatitis C and HIV), increase the number of individuals receiving medication-assisted treatment (MAT), increase the proportion retained in treatment beyond 6 months, and increase the number of individuals receiving needed recovery support services. DATES: The RFI is open for public comment for a period of 21 days. Comments must be received by July 20, 2018 to ensure consideration. ADDRESSES: Comments must be submitted electronically to the following email address: [email protected]. FOR FURTHER INFORMATION CONTACT: Please direct all inquiries to Redonna K. Chandler, Ph.D., National Institute on Drug Abuse; Phone: 301-443- 1470; email: [email protected]. SUPPLEMENTARY INFORMATION: This RFI is for information and planning purposes only, and should not be construed as a solicitation or an obligation on the part of the federal government, the National Institutes of Health (NIH), the National Institute on Drug Abuse (NIDA), or the Substance Abuse and Mental Health Services Administration (SAMHSA). NIH does not intend to make any awards based on responses to this RFI or to otherwise pay for the preparation of any information submitted or for the government's use of such information. Terminology: This RFI is focused on the use, misuse, abuse of opioids, and OUD. Opioids include prescription and illicit opioids, such as heroin, illicitly manufactured fentanyl, and related analogs. OUD refers to the clinical diagnosis defined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Problem Statement: Despite the availability of multiple effective evidence-based interventions and practices, most Americans at risk for or suffering from an OUD do not receive appropriate prevention and treatment services. Simultaneously, opioid overdose rates continue to increase. NIDA, in partnership with SAMHSA, is exploring options for conducting a multi-site national research effort in up to three communities to develop and test approaches for the systematic implementation and sustainability of an integrated set of evidence- based interventions across healthcare, behavioral health, justice systems, state and local governments, and community organizations to prevent and treat opioid misuse and OUD. The goals are to decrease fatal and non-fatal overdoses, decrease the incidence of OUD and related infectious diseases (e.g., Hepatitis C and HIV), increase the number of individuals receiving medication-assisted treatment (MAT), increase the proportion retained in treatment beyond 6 months, and increase the number of individuals receiving needed recovery support services. This research would be a part of the NIH Helping to End Addiction Long-term (HEAL) Initiative (https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative). Information Requested: This RFI solicits input from the extramural research community and public stakeholders. NIDA and SAMHSA especially seek input on study elements such as, but not limited to: Study Design:How can ``heavily affected communities'' be defined, including geospatial/geopolitical definitions to provide consistent boundaries for a multi-site study? What research designs might be appropriate to accomplish the overall goals of the study? How can effect size be estimated and what effect size might be expected in relation to candidate outcomes: Rates of non-fatal and fatal overdose; prevalence and incidence of opioid misuse, OUD and Hepatitis C; percent of patients screened for opioid misuse and OUD and who received a brief intervention or were referred to treatment; percent of patients initiated on MAT and retained in medication treatment beyond 6 months; rates of naloxone distribution and overdose reversals; opioid analgesic and benzodiazepine prescription rates; and implementation of prevention programs? What baseline data should be captured, what are potential existing sources for this data, and what challenges might exist with quality of existing data? How long would an integrated set of evidence-based interventions need to be in place before expecting a meaningful change in outcomes, and which combination of interventions should be implemented in communities with different characteristics? What confounding variables need to be considered? What are potential threats to internal and external study validity and what strategies could be deployed to mitigate threats? Are there particular strategies that can help the Coordinating Center overcome barriers to the facilitation of collaboration and coordination activities across Research Centers with regard to data harmonization, collection, integration, cleaning, analyses, and creating datasets for sharing with the research community at large? Outcomes: What target metrics would be feasible for outcomes? Candidate outcomes could include, but are not limited to those listed above: Rates of non-fatal and fatal overdose; prevalence and incidence of opioid misuse, OUD and Hepatitis C; percent of patients screened for opioid misuse and OUD and who received a brief intervention or were referred to treatment; percent of patients initiated on MAT and retained in medication treatment beyond 6 months; rates of naloxone distribution and overdose reversals; opioid analgesic and benzodiazepine prescription rates; and implementation of prevention programs? What is the best way to gather reliable data related to candidate outcomes listed above? What are essential interventions for an evidence-based integrated approach to opioid prevention and treatment services, including policies and practices? How could ``evidence-based or evidence-informed'' be defined? How can fidelity to an evidence-based integrated approach to opioid prevention and treatment services, including policies and practices be measured? What strategies and resources would be necessary, including training and technical assistance, to have meaningful penetration of the evidence- [[Page 30757]] based integrated approach to opioid prevention and treatment services in a single community? Health Economics: What economic questions should be included as part of the study to inform systems and policy change? Implementation Research: What implementation research questions should be included to develop best practices for replication in other communities impacted by the opioid crisis? What data should be collected to help develop metrics for determining the quality of an integrated approach to opioid prevention and treatment services, including policies and practices? Are there examples of prior implementation research studies that highlight implementation tools that can be used to replicate and scale up integrated approaches? Infrastructure, Partnerships, Collaboration: What research, prevention, and treatment infrastructure and partnerships are needed to support a community-based pragmatic trial assessing the impact of an evidence-based integrated approach to opioid prevention and treatment services? What is the best approach to fostering collaboration and meaningful participation between state, county, and local governments; community stakeholders; medical/clinical service providers; and researchers? How do we construct a research initiative with the highest likelihood of having sustainable prevention and treatment services? What data would be of most interest to state and community partners? Responses to this RFI are voluntary and may be submitted anonymously. Please do not include any personally identifiable or other information that you do not wish to make public. Proprietary, classified, confidential, or sensitive information should not be included in responses. Comments submitted will be compiled for discussion and shared internally with NIDA, SAMHSA, NIH program staff, and participating leadership across the Department of Health and Human Services, as appropriate. Any personal identifiers (personal names, email addresses, etc.) will be removed when responses are compiled. This RFI is for informational and planning purposes only and is not a solicitation for applications or an obligation on the part of the United States Government to provide support for any ideas identified in response to it. Please note that the United States Government will not pay for the preparation of any information submitted or for use of that information. Dated: June 25, 2018. Lawrence A. Tabak, Deputy Director, National Institutes of Health. [FR Doc. 2018-14031 Filed 6-28-18; 8:45 am] BILLING CODE 4140-01-P
![Federal Register / Vol. 83, No. 126 / Friday, June 29, 2018 / Notices 30757
based integrated approach to opioid Government will not pay for the Contact Person: Najma S. Begum, Ph.D.,
prevention and treatment services in a preparation of any information Scientific Review Officer, Review Branch,
single community? submitted or for use of that information. DEA, NIDDK, National Institutes of Health,
Health Economics: Room 7349, 6707 Democracy Boulevard,
Dated: June 25, 2018. Bethesda, MD 20892–5452, (301) 594–8894,
• What economic questions should be begumn@niddk.nih.gov.
Lawrence A. Tabak,
included as part of the study to inform
Deputy Director, National Institutes of Health. Name of Committee: National Institute of
systems and policy change? Diabetes and Digestive and Kidney Diseases
Implementation Research: [FR Doc. 2018–14031 Filed 6–28–18; 8:45 am]
Special Emphasis Panel; T1D Clinical Trials
• What implementation research BILLING CODE 4140–01–P
Testing Current and Novel Closed Loop
questions should be included to develop Systems (R01).
best practices for replication in other Date: July 24, 2018.
communities impacted by the opioid DEPARTMENT OF HEALTH AND Time: 3:00 p.m. to 5:00 p.m.
crisis? HUMAN SERVICES Agenda: To review and evaluate grant
• What data should be collected to applications.
help develop metrics for determining National Institutes of Health Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
the quality of an integrated approach to Boulevard, Bethesda, MD 20892 (Telephone
National Institute of Diabetes and
opioid prevention and treatment Conference Call).
Digestive and Kidney Diseases; Notice
services, including policies and Contact Person: Jason D. Hoffert, Ph.D.,
of Closed Meetings
practices? Scientific Review Officer, Review Branch,
• Are there examples of prior Pursuant to section 10(d) of the DEA, NIDDK, National Institutes of Health,
implementation research studies that Federal Advisory Committee Act, as Room 7343, 6707 Democracy Boulevard,
highlight implementation tools that can Bethesda, MD 20817, 301–496–9010,
amended, notice is hereby given of the hoffertj@niddk.nih.gov.
be used to replicate and scale up following meetings.
integrated approaches? Name of Committee: National Institute of
The meetings will be closed to the Diabetes and Digestive and Kidney Diseases
Infrastructure, Partnerships, public in accordance with the Special Emphasis Panel; RFA–DK–17–020:
Collaboration: provisions set forth in sections Immune System Engineering for Targeted
• What research, prevention, and 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Tolerance in Type 1 Diabetes (R01).
treatment infrastructure and as amended. The grant applications and Date: July 25, 2018.
partnerships are needed to support a the discussions could disclose Time: 11:00 a.m. to 4:30 p.m.
community-based pragmatic trial confidential trade secrets or commercial Agenda: To review and evaluate grant
assessing the impact of an evidence- applications.
property such as patentable material, Place: National Institutes of Health, Two
based integrated approach to opioid and personal information concerning
prevention and treatment services? Democracy Plaza, 6707 Democracy
individuals associated with the grant Boulevard, Bethesda, MD 20892 (Telephone
• What is the best approach to
applications, the disclosure of which Conference Call).
fostering collaboration and meaningful
would constitute a clearly unwarranted Contact Person: Dianne Camp, Ph.D.,
participation between state, county, and Scientific Review Officer, Review Branch,
invasion of personal privacy.
local governments; community DEA, NIDDK, National Institutes of Health,
stakeholders; medical/clinical service Name of Committee: National Institute of Room 7013, 6707 Democracy Boulevard,
providers; and researchers? Diabetes and Digestive and Kidney Diseases Bethesda, MD 20892–2542, 301–594–7682,
• How do we construct a research Special Emphasis Panel; T1D NIDDK Review. campd@extra.niddk.nih.gov.
Date: June 29, 2018.
initiative with the highest likelihood of Time: 9:00 a.m. to 1:00 p.m. Name of Committee: National Institute of
having sustainable prevention and Diabetes and Digestive and Kidney Diseases
Agenda: To review and evaluate grant
treatment services? Special Emphasis Panel; SBIR Phase II
applications.
• What data would be of most interest Place: National Institutes of Health, Two
Clinical Trials.
to state and community partners? Date: July 26, 2018.
Democracy Plaza, 6707 Democracy
Time: 11:00 a.m. to 1:00 p.m.
Responses to this RFI are voluntary Boulevard, Bethesda, MD 20892 (Telephone
Agenda: To review and evaluate grant
and may be submitted anonymously. Conference Call).
applications.
Please do not include any personally Contact Person: Elena Sanovich, Ph.D.,
Place: National Institutes of Health, Two
identifiable or other information that Scientific Review Officer, Review Branch,
Democracy Plaza, 6707 Democracy
you do not wish to make public. DEA, NIDDK, National Institutes of Health, Boulevard, Bethesda, MD 20892 (Telephone
Room 7351, 6707 Democracy Boulevard,
Proprietary, classified, confidential, or Bethesda, MD 20892–2542, 301–594–8886,
Conference Call).
sensitive information should not be Contact Person: Thomas A. Tatham, Ph.D.,
sanoviche@mail.nih.gov. Scientific Review Officer, Review Branch,
included in responses. Comments This notice is being published less than 15
submitted will be compiled for DEA, NIDDK, National Institutes of Health,
days prior to the meeting due to the timing Room 7021, 6707 Democracy Boulevard,
discussion and shared internally with limitations imposed by the review and Bethesda, MD 20892–5452, (301) 594–3993,
NIDA, SAMHSA, NIH program staff, funding cycle. tathamt@mail.nih.gov.
and participating leadership across the Name of Committee: National Institute of Name of Committee: National Institute of
Department of Health and Human Diabetes and Digestive and Kidney Diseases Diabetes and Digestive and Kidney Diseases
Services, as appropriate. Any personal Special Emphasis Panel; RFA–DK–17–021: Special Emphasis Panel; PAR–18–042:
identifiers (personal names, email HIRN Consortium on Beta Cell Death and NIDDK Ancillary Studies (R01).
addresses, etc.) will be removed when Survival Early T1D Biomarkers Discovery in Date: July 26, 2018.
Human Pancreas. Time: 11:30 a.m. to 1:30 p.m.
sradovich on DSK3GMQ082PROD with NOTICES
responses are compiled.
This RFI is for informational and Date: July 23, 2018. Agenda: To review and evaluate grant
planning purposes only and is not a Time: 11:00 a.m. to 4:00 p.m. applications.
Agenda: To review and evaluate Place: National Institutes of Health, Two
solicitation for applications or an cooperative agreement applications. Democracy Plaza, 6707 Democracy
obligation on the part of the United Place: National Institutes of Health, Two Boulevard, Bethesda, MD 20892 (Telephone
States Government to provide support Democracy Plaza, 6707 Democracy Conference Call).
for any ideas identified in response to Boulevard, Bethesda, MD 20892 (Telephone Contact Person: Ann A. Jerkins, Ph.D.,
it. Please note that the United States Conference Call). Scientific Review Officer, Review Branch,
VerDate Sep<11>2014 17:58 Jun 28, 2018 Jkt 244001 PO 00000 Frm 00075 Fmt 4703 Sfmt 4703 E:\FR\FM\29JNN1.SGM 29JNN1](https://thefederalregister.org/doc/83_FR_30882/page/2.svg)
Document Created: 2018-06-29 01:13:22
Document Modified: 2018-06-29 01:13:22
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notice. | |
| Dates | The RFI is open for public comment for a period of 21 days. Comments must be received by July 20, 2018 to ensure consideration. | |
| Contact | Please direct all inquiries to Redonna K. Chandler, Ph.D., National Institute on Drug Abuse; Phone: 301-443- 1470; email: [email protected] | |
| FR Citation | 83 FR 30756 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR